Humacyte Acellular Tissue Engineered Vessel (ATEV™)

May 26, 2026 — Humacyte, Inc. (Nasdaq: HUMA) announced a research presentation at the Vascular Access Society of the Americas (VASA) 2026 Vascular Access for Dialysis Symposium (Salt Lake City) on self-repair of its acellular tissue engineered vessel (ATEV) after repeated cannulation for hemodialysis access.

Histological analyses of explanted AV access conduits used for up to 5.5 years compared ATEV with ePTFE grafts. In explants up to 5.5 years post-implantation, ATEVs were observed to maintain long-term structural integrity and showed evidence of self-repair at cannulation sites, including smooth muscle cell repopulation, capillary ingrowth, organized collagen deposition (predominant collagen III), and markers consistent with matrix regeneration. Humacyte also reported ATEVs were observed to have greater resistance to bacterial infection than ePTFE at cannulation sites and adjacent vessel walls.

Business/clinical significance: The findings support continued evaluation of ATEV as a durable, self-repairing, potentially infection-resistant dialysis access option. Humacyte expects top-line interim results from its V012 Phase 3 dialysis access study (focused on female ESRD patients) to be reported June 11, 2026 at SVS VAM, and plans an sBLA for a hemodialysis AV access indication in 2H 2026 contingent on results.